Past year
All results
- All results
- Verbatim
Jul 3, 2024 · Background. Increasing evidence supports the use of plasma biomarkers of amyloid, tau, neurodegeneration, and neuroinflammation for diagnosis of dementia.
Oct 13, 2023 · CSF biomarkers can be used to detect both Aβ and tau peptides and, in most patients, alterations in these biomarkers can be detected earlier than changes in ...
Feb 21, 2024 · The presence of Aβ pathology can be determined by positron emission tomography (PET), which visualizes Aβ deposition in the brain, or cerebrospinal fluid (CSF) ...
Sep 17, 2024 · Alzheimer's disease biomarkers are positive in around 50% of patients with dementia with Lewy bodies and are associated with worse cognition.
Missing: novel | Show results with:novel
Nov 14, 2023 · Data from these studies suggest that reduced Aβ and increased tau, but not α-syn in CSF can be predictors of cognitive decline in PD. In DLB patients, Aβ1-42 ...
May 15, 2024 · This literature review focuses on plasma neurofilament light (NfL) and CSF NfL as blood-based biomarkers used in recent AD diagnosis.
3 days ago · Pathological imaging and CSF AD biomarkers are associated with a higher likelihood of cognitive decline in LBD but do not always mirror the neuropathological ...
Jun 4, 2024 · Our study suggests a possible utility of plasma Aβ42/40, P-tau181, and P-tau231 as a noninvasive biomarkers to assess amyloid copathology in DLB.
Oct 28, 2023 · Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET).
Missing: novel | Show results with:novel
Feb 15, 2024 · Beta Amyloid. Aβ1–42 in CSF is one of the core AD biomarkers, showing a decrease by approximately 50% in patients who actively deposit Aβ in the ...
